Related Experiment Video
Updated: Jul 6, 2026
09:25
Bioluminescent Orthotopic Model of Pancreatic Cancer Progression
Published on: June 28, 2013
Research funding for palliative medicine
Laura P Gelfman1, R Sean Morrison
1Hertzberg Palliative Care Institute of the Brookdale Department of Geriatrics, Mount Sinai School of Medicine, New York, New York 10029, USA.
Journal of Palliative Medicine
|March 29, 2008
Summary
Palliative medicine research funding is insufficient, with federal support particularly lacking. This limits advancements in care for seriously ill patients and their families.
Area of Science:
- Medical Research
- Palliative Care
- Health Services Research
Background:
- Inadequate medical care for seriously ill patients necessitates greater investment in palliative medicine research.
- Previous reports highlight the need for enhanced funding in this critical area.
Purpose of the Study:
- To identify funding sources for palliative medicine research published between 2003-2005.
- To examine the National Institutes of Health (NIH) funding of palliative medicine research from 2001-2005.
Main Methods:
- Systematic review of adult palliative medicine research publications (2003-2005) from major and specialty journals.
- Identification of funding sources for 388 research articles and 2,197 investigators.
- Cross-matching of U.S. palliative medicine researchers with NIH grant databases (2001-2005).
Main Results:
- 72% of identified palliative medicine research articles received extramural funding.
- Foundations (51%) and the National Institutes of Health (NIH) (31%) were primary funding sources.
- Only 109 investigators received NIH funding, with the National Cancer Institute (NCI), National Institute of Nursing Research (NINR), and National Institute on Aging (NIA) funding 85% of NIH awards.
Conclusions:
- Palliative medicine research funding, especially federal support, is inadequate.
- Insufficient funding hinders improvements in care for seriously ill patients and their families.
Related Concept Videos
01:25Continuing Care
Continuing care describes the variety of health, personal, and social services provided over a prolonged period. The need for continuing care is increasing because people are living longer. Many people do not have families or others to care for them. Continuing care is mainly for patients who are disabled, functionally dependent, or suffering from a terminal disease. It is available within institutional settings or in homes. Examples include nursing centers or facilities, assisted living,...
01:27Nursing Ethical Principles II
Ethical principles are essential in guiding nurses to fulfill their responsibilities, focusing on the quality of nursing care and decision-making. These principles, including autonomy, beneficence, non-maleficence, justice, and fidelity, shape the ethical framework within healthcare settings.
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's cancer...
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's cancer...
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...